An Ascending Single Dose Study of the Pharmacokinetics, Safety and Tolerability of Hemay005 in Healthy Male Subjects

Trial Profile

An Ascending Single Dose Study of the Pharmacokinetics, Safety and Tolerability of Hemay005 in Healthy Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Hemay 005 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Tianjin Hemay Biotech
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
    • 07 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top